Steven W. King

Insider Reports History

SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Paul Lytle, as attorney-in-fact for Steven King
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Steven W. King

Form 4 holding Director

Oncotelic Therapeutics, Inc.

Security class
Stock Options
Shares / value
500,000
Estimated value
Report date
03 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director, 10%+ Owner

Mosaic ImmunoEngineering Inc.

Security class
Convertible Note
Shares / value
$20,000
Estimated value
Report date
18 Feb 2022
Price
Ownership
Direct
Underlying class
See footnotes
Underlying amount

Insider Reports Filed by Steven W. King

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .